05 March 2026
: Case report 
Bilateral Eales’ Disease Managed With Vitrectomy and Anti-VEGF Therapy: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Zuzanna Lelek
ABCDEF 1, Martyna Machaj ABCDEF 1, Katarzyna Krysik F 1,2, Dominika Janiszewska-Bil E 1,3, Dariusz Dobrowolski F 1,4,5, Sylwia Ewa Szendzielorz-Krzempek B 6, Beniamin Oskar Grabarek EF 3,7, Anita Lyssek-Boroń DE 1,2*
DOI: 10.12659/AJCR.950820
Am J Case Rep 2026; 27:e950820
Table 1 Chronology of interventions and outcomes in a 32-year-old man with bilateral Eales’ disease.
| Time from presentation | Eye | Intervention/systemic therapy | Outcome (BCVA, logMAR) |
|---|---|---|---|
| Baseline | Left (OS) | Diagnosis: vitreous hemorrhage, vitreoretinal traction, peripheral ischemia | Hand motion (≈2.3) |
| Baseline | Right (OD) | Diagnosis: peripheral ischemia, prior PRP scars | 5/6 (≈0.08) |
| Month 0 | OS | Vitrectomy + phacoemulsification + IOL implantation + endolaser photocoagulation + SF6 tamponade | – |
| Months 1–3 | Both eyes (OU) | Systemic immunosuppression: azathioprine 50 mg twice daily for 2 months (Imuran, Aspen Pharma), switched to methotrexate 7.5 mg weekly (Methotrexate, Koçak Farma) with folic acid 5 mg weekly (Acidum folicum, Teva) administered the day after methotrexate; CBC and LFT monitoring within normal limits | Stable |
| Month 12 | OD | Disease reactivation treated with intravenous methylprednisolone 500 mg/day for 3 days (Prednol-L, Mustafa Nevzat) and PRP | – |
| Month 12+ | OD | Oral methylprednisolone taper (Medrol, Pfizer), topical dexamethasone 1% eye drops (Maxidex, Novartis), and pantoprazole 40 mg/day (Controloc, Takeda) | – |
| Month 12+ | OD | Intravitreal faricimab 6 mg (Vabysmo, Roche/Genentech) administered preoperatively | – |
| Month 12 | OD | Vitrectomy + phacoemulsification + IOL implantation + fibrovascular tissue removal + 360° endolaser photocoagulation + SF6 tamponade | – |
| Month 18 (OS)/12 (OD) | OU | Final follow-up | 5/5 (0.00) bilaterally |
| BCVA – best-corrected visual acuity; CBC – complete blood count; IOL – intraocular lens; IV – intravenous; LFT – liver function test; logMAR – logarithm of the minimum angle of resolution; OCT – optical coherence tomography; PRP – panretinal photocoagulation; SF – sulfur hexafluoride gas. | |||